American Society of Anesthesiologists Calls For Stronger Ketamine Oversight As Use Surges
Ketamine treatment has expanded quickly, from medical settings into mental health clinics, telehealth programs and home delivery models. Now one of the country’s most influential anesthesia groups is warning that safety standards have not kept pace.
The American Society of Anesthesiologists is calling for stronger oversight of ketamine prescribing and delivery, especially when the drug is used at home or without direct physician supervision. That matters because anesthesiologists are not outside commentators. They are the physicians most closely associated with ketamine’s use as an anesthetic, and their warning carries clinical weight.
Looking for treatment? Find Spravato clinics (which is covered by insurance) and  ketamine clinics closest to you as well as other psychedelic therapies in your area.
Key Takeaways
| Key takeaway | Why it matters |
|---|---|
| A major medical society is raising the alarm | The American Society of Anesthesiologists has direct experience with ketamine as a powerful anesthetic. Its concern gives the issue more authority. |
| The concern is about oversight, not access alone | Ketamine may help some patients with depression, PTSD and pain. The question is whether care models include enough screening and monitoring. |
| At home ketamine is the biggest flashpoint | Home delivery can make treatment easier to access, but it can also remove direct medical supervision during a drug experience. |
| Ketamine is not a low risk wellness product | It can affect breathing, blood pressure, heart rate, perception and judgment. Those risks need a safety plan. |
| Standards vary across providers | A hospital based infusion, a psychiatric clinic and a telehealth prescription may all involve ketamine, but they may not involve the same safeguards. |
| Patients need to know what safe care looks like | Screening, supervision, emergency planning and follow up should be part of treatment, not optional extras. |
Why The ASA Warning Matters
The American Society of Anesthesiologists is not a fringe voice in this debate. It represents physicians who work with anesthetic drugs every day. Ketamine is one of those drugs.
That is why the group’s call for stronger oversight matters. It does not come from fear of innovation. It comes from familiarity with the medication’s power.
Ketamine can be useful. It can also be unpredictable. In medical settings, clinicians monitor vital signs, breathing, sedation and mental status. They know when a patient needs intervention.
The ASA is now arguing that ketamine used for mental health should not be treated as less serious because it is used outside the operating room.
The Growth Has Been Faster Than The Rules
Ketamine is FDA approved as an anesthetic. Clinicians may prescribe it off label for psychiatric conditions, which is legal and common in medicine.
But off label use creates a looser landscape. Different clinics may use different screening forms, dosing plans and monitoring protocols. Telehealth platforms add another layer. Some prescribe ketamine remotely and send it to a patient’s home.
That model can appeal to patients who want privacy, convenience or lower costs. But convenience is not the same as clinical safety.
The U.S. ketamine market has already surpassed $5 billion and is projected to grow sharply. That growth has brought more patients into care. It has also brought more concern about what happens when access expands faster than regulation.
What The Risks Look Like
Ketamine can cause dissociation, sedation and changes in perception. It can also affect blood pressure and heart rate. In some cases, it may contribute to breathing problems, especially when combined with other sedating medications.
Those risks do not mean ketamine should disappear from mental health care. They mean the setting matters.
A supervised clinic can check blood pressure, watch for distress and respond to complications. At home, the patient may be alone. They may not recognize a dangerous reaction. They may also take other medications that increase risk.
That is the gap the ASA wants policymakers to address.
What Patients Should Ask
Patients considering ketamine should not have to guess whether a provider is being careful.
A strong program should ask about heart health, blood pressure, substance use history, psychosis risk and current medications. It should explain who monitors the session. It should also have a plan for anxiety, blood pressure changes or excessive sedation.
Follow up matters too. Ketamine should not feel like a one time transaction. Patients need symptom tracking, integration support and a clear plan after each dose.
The Bigger Takeaway
The ASA’s warning does not erase ketamine’s promise. It sharpens the conversation around it.
Patients deserve access to new options, especially when standard treatments have failed. They also deserve care that treats ketamine like medicine, not a convenience product.
The best future for ketamine therapy is not less access. It is better access. That means stronger standards, clearer oversight and more consistent protection for the people seeking help.
